RA ℞: Anti-TNF

The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.

There is no practical difference between the various TNF inhibitors, in terms of clinical response or side effects.

Responders will respond fast enough, like, in 1-2 weeks. Those who don’t are primary inadequate responders, and should be switched to another targeted therapy with a different mode of action.

Try non-TNF biologics for RA if anti-TNF fails

Rheumatoid arthritis patients who were unsuccessfully treated with anti–tumor necrosis factor drugs fared significantly better when treated with a non-TNF biolo